FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $6,075,724 | -16.9% | 602,153 | +84.5% | 0.19% | -22.2% |
Q3 2022 | $7,315,000 | +12.2% | 326,419 | +24.0% | 0.24% | +7.2% |
Q2 2022 | $6,521,000 | -17.9% | 263,156 | +28.4% | 0.22% | +13.2% |
Q1 2022 | $7,946,000 | +1.8% | 204,945 | +53.6% | 0.20% | +22.4% |
Q4 2021 | $7,805,000 | +76.8% | 133,401 | +79.1% | 0.16% | +91.7% |
Q3 2021 | $4,415,000 | – | 74,492 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
XTX Topco Ltd | 192,920 | $408,990 | 0.07% |